Abstract
Systemic sclerosis (SSc) is an autoimmune disorder and may affect the skin, blood vessels, and internal organs. A higher incidence of malignancy in SSc patients has been reported. We herein report a case of a patient with breast cancer and scleroderma. A 53-year-old woman was referred to our hospital for treatment of scleroderma. An irregularly-shaped mass was found on screening CT in the lower-lateral area of the left breast. A core needle biopsy showed invasive ductal carcinoma. The patient underwent a left mastectomy and sentinel lymph node biopsy followed by adjuvant chemotherapy (FEC : fluorouracil, epirubicin, and cyclophosphamide). However, a liver metastasis was observed 4 months after the surgery. She received first-line chemotherapy with doxorubicin (A) and cyclophosphamide (C), and then switched to hormonal therapies (ANA, EXE) with stable disease. After two different types of chemotherapy (UFT [uracil and tegafur] and eribulin mesylate) and hormonal therapies for metastatic disease, the patient finally died 3.6 years after surgery. Treatments for breast cancer in SSc patients should be carefully selected depending on the clinical condition.
